#### **AACR Bulletin Board**

#### **Institution of Page Charges**

Effective January 1, 1997, a page charge of \$35 per printed page was levied on all manuscripts published in Clinical Cancer Research. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

#### **Annual Meeting**

The AACR's Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in San Diego, CA, April 12–16, 1997. The Chairperson of the Annual Meeting is Frederick P. Li of the Dana-Farber Cancer Institute. Clara Derber Bloomfield of the Roswell Park Memorial Institute and Stephen H. Friend of the Fred Hutchinson Cancer Research Center will serve as Co-Chairpersons. The Program Committee has invited outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. They are also now reviewing the proffered papers submitted by members of the cancer research community. The deadline for abstract submissions was November 12, 1996. Up-to-date program information can be obtained via the Internet at the AACR's website (http://www.aacr.org/meetings.html).

#### Workshop on Molecular Biology in **Clinical Oncology**

The AACR will sponsor an intensive, oneweek summer workshop on molecular biology designed for clinical oncologists in training and in their early academic careers. The workshop will take place at the Given Biomedical Institute in Aspen, Colorado, from June 27-July 3, 1997. Recent advances in molecular biology are becoming more and more relevant to the diagnosis, therapy, and management of cancer patients. The workshop will give clinical oncologists the opportunity to interact closely in an informal setting with experts in the field of molecular biology, learn their language and laboratory techniques, better understand relevant literature, and communicate more effectively with their basic science colleagues.

Stephen H. Friend of the Fred Hutchinson Cancer Research Center, L. Michael Glodé of the University of Colorado School of Medicine, and Jennifer A. Pietenpol of the Vanderbilt University School of Medicine will serve as chairpersons of the workshop and will invite a distinguished faculty to direct five 21/2-hour laboratory sessions and deliver 20 hours of lectures. Generous support from the National Cancer Institute will provide funding for the registration fees and hotel accommodations of 65 physicians in training and oncology fellows. Ten senior clinical oncologists will also be able to attend the workshop upon payment of a registration

#### **AACR**

The American Association for Cancer Research (AACR) was founded in 1907 to bring together active investigators of the cancer problem for the presentation and discussion of new findings and to foster advances in cancer research. Today the Association has more than 12,000 members working in all of the subdisciplines of cancer research in the United States, Canada, and more than 50 other countries. Information on AACR programs and activities can be obtained from

American Association for Cancer Research **Public Ledger Building** 150 South Independence Mall West Suite 816 Philadelphia, PA 19106-3483 Phone: (215) 440-9300 Fax: (215) 440-9313 E-mail: aacr@aacr.org

The AACR welcomes applications for membership from the readership. Scientists engaged in all areas of cancer research are eligible for membership. There are three categories of membership: active membership, open to cancer researchers working in the Americas; corresponding membership, to those working outside the Americas; and associate membership, to graduate and medical students, postdoctoral fellows, and physicians-in-training. Further information on the qualifications for each category as well as the benefits of membership can be found on the application forms at the back of this issue.

Information and application forms were mailed to AACR members in February. Nonmembers should request brochures from the AACR office.

#### Workshop on Methods in Clinical Cancer Research

This July the AACR and the American Society of Clinical Oncology (ASCO) will sponsor a six-day summer workshop on clinical research methods designed for both oncologists in training and senior investigators. The workshop will take place at the Vail Cascade Hotel and Club in Vail, Colorado, from July 26 to August 1, 1997. The overall goal of the workshop will be to educate clinical scientists in methods for clinical research and to encourage better clinical trial design so that new cancer treatments can be introduced more rapidly into general medical practice. Major support for this program has already been obtained from the National Cancer Institute. Bristol-Myers Squibb, and Amgen. Funds will be available to offset the registration fees and housing and subsistence expenses for 75 clinical trainees to attend the workshop. In addition, 25 clinical investigators at the level of junior faculty will be accepted to the workshop upon payment of a registration fee. (Some travel support will

also be available for junior faculty.)
The Workshop Organizing Committee is chaired by Drs. Daniel D. Von Hoff (for AACR) and Charles A. Coltman, Jr. (for

ASCO), both of the Cancer Therapy and Research and Research Center in San Antonio, Texas. They will invite and select a distinguished faculty that will deliver over 20 hours of lectures on a variety of topics in the field and direct eight small-group discussion sessions in which 15-20 participants can review important aspects of the design of clinical trials. In addition, each participant will be responsible for the preparation of an actual protocol for a clinical trial while attending the workshop. Groups of six to eight students will meet with two assigned faculty members on several occasions during the week to review intermediate drafts of these protocols. ASCO will certify this workshop for Category 1 credits toward the AMA Physicians Recognition Award.

Information and application forms will be mailed to AACR and ASCO members in March. Nonmembers should request brochures from the AACR office.

#### **AACR Special Conferences in** Cancer Research

A number of meetings are now being organized in the AACR's series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for some of these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. FAX: (215) 440-9313. E-Mail: aacr@aacr.org. Up-to-date program information is available via the Internet from information is available via the Internet from the AACR's website (http://www.aacr.org/ confrnc.html).

March 7-12, 1997 Basic and Clinical Aspects of Breast Cancer

Chairpersons:

J. CARL BARRETT, Research Triangle Park,

KAREN S. H. ANTMAN, New York, NY MARY-CLAIRE KING, Seattle, WA Keystone Resort, Keystone, CO

June 7-11, 1997 Cancer of the Central Nervous System Conference with Neurosurgery Joint Section

Chairpersons:

PETER McL. BLACK, Boston, MA WEBSTER K. CAVENEE, La Jolla, CA Loews Coronado Bay Resort, San Diego,

September 26-30, 1997 **Tumor Suppressor Genes** 

Co-Sponsored by the National Cancer Institute of Canada

Chairpersons:

PHILIP BRANTON, Montreal, Quebec,

STEPHEN H. FRIEND, Seattle, WA Victoria Conference Centre, Victoria, BC. Canada

#### **Instructions for Authors**

#### Scope

Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

#### **Editorial Policy**

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in *Clinical Cancer Research*, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the *Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education* issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for \$5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator's Institutional Review Board.

#### Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

#### **Publication Fees**

A page charge of \$35 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Depart-

ment (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

#### **Procedures for Submission**

Submit papers directly to one of the six Senior Editors, each of whom is responsible for a particular area of research. Senior Editors will conduct the review process with the expert assistance of the journal's Associate Editors, will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

#### **Format**

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

- Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
- 2. A running title of fewer than 50 characters;
- 3. Three to five key words that do not appear in the title;
- Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
- Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
- Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
- Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
- Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;
- 9. Figures.

#### References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

#### **SAMPLE REFERENCES:**

- 1. Shaffer, D. W., Smith, L. S., Burris, H. A., Clark, G. M., Eckardt, J. R., Fields, S. M., Weiss, G. R., Rinaldi, D. A., Bowen, K. J., Kuhn, J. G., and Von Hoff, D. D. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res., 53: 5929-5933, 1993.
- 2. Dimaggio, J. J., Scheinberg, D. A., and Houghton, A. N. Monoclonal antibody therapy of cancer. In: H. M. Pinedo, B. A. Chabner, and D. L. Longo (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual, Vol. 11, pp. 177-203. Amsterdam: Elsevier Science Publishers B.V., 1990.

#### **Figures**

Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is \$975 per color figure. Submit color figures on flexible backing.

#### **Proofs**

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors' corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

#### Typesetting Manuscripts from Computer Disks

Clinical Cancer Research requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

#### Research Areas of the Editor-in-Chief and Senior Editors

John Mendelsohn, M.D., Editor-in-Chief

Department of Educational Publishing Services-227 The University of Texas M. D. Anderson Cancer Center

1515 Holcombe Boulevard Houston, TX 77030 Telephone: 713-792-6014 Fax: 713-792-6016

E-mail: jmendelsohn@notes.mdacc.tmc.edu

Cell proliferation and death—preclinical, and clinical trials; radiation therapy, surgery, and subspecialty investigation

Waun Ki Hong, M.D., Deputy Editor

Department of Thoracic/Head & Neck Medical Oncology The University of Texas M. D. Anderson Cancer Center Box 80 1515 Holcombe Boulevard Houston, TX 77030

Telephone: 713-792-6363 Fax: 713-796-8655

E-mail: waun\_hong@isqm.mda.uth.tmc.edu

Clinical trials targeted at specific malignancies, chemoprevention

Lance A. Liotta, M.D., Ph.D. Laboratory of Pathology

National Cancer Institute Building 10, Room 2A33 National Institutes of Health

10 Center Drive, MSC 1500 Bethesda, MD 20892-1500 Telephone: 301-496-3185

Fax: 301-402-0043

E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.

Otolaryngology/Head & Neck Cancer Research

Johns Hopkins University 818 Ross Research Building 720 Rutland Avenue Baltimore, MD 21205-2196

Telephone: 410-550-5153 Fax: 410-614-1411

E-mail: dsidrans@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.

Departments of Pediatrics, Human Oncology, & Genetics University of Wisconsin Clinical Science Center

K4/448

600 Highland Avenue Madison, WI 53792 Telephone: 608-263-9069

Fax: 608-263-4226

E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines-preclinical, and clinical trials

David R. Spriggs, M.D.

Developmental Chemotherapy Service Memorial Sloan-Kettering Cancer Center

1275 York Avenue New York, NY 10021 Telephone: 212-639-2203 Fax: 212-717-3272

E-mail: dspriggs@pop.ski.mskcc.org

Preclinical pharmacology, pharmacological clinical trials

Jeffrey M. Trent, Ph.D.

Laboratory of Cancer Genetics

National Center for Human Genome Research

National Institutes of Health Building 49, Room 4A22 49 Convent Drive, MSC 4470 Bethesda, MD 20892-4470

Telephone: 301-402-2023 Fax: 301-402-2040

E-mail: jtrent@nchgr.nih.gov

Genetics, cytogenetics

#### For more information, contact:

John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, Department of Educational Publishing Services-227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, Telephone 713-792-6014, Fax 713-792-6016

Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483, Telephone 215-440-9300, Fax 215-440-9355.

# SUCAN ASSOCIATION OF THE STATE OF THE STATE

#### AMERICAN ASSOCIATION FOR CANCER RESEARCH

## GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

#### BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 11,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

- 1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
- an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
- 3. reduced registration rates at annual meetings;
- 4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
- 5. substantially reduced registration rates for Special Conferences;
- opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
- 7. receipt of AACR Newsletters and other important announcements;
- early notification of and reduced rates for participation in the AACR Employment Register;
- 9. an up-to-date Membership Directory of over 11,500 member researchers in the cancer field;
- the professional benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
- the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
- 12. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
- 13. many more ongoing benefits.

#### QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

#### PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships

Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application
in AACR Office

January 1

May 1

September 1

November

A complete application consists of the following material:

- 6 copies of the form on the opposite side of this page, with all requested information provided.
- 5 copies of the candidate's most current curriculum vitae and bibliography.
- 3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. —OR— The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
- 4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). -OR- The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
- 5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research Public Ledger Building, Suite 816 150 S. Independence Mall West Philadelphia, PA 19106-3483 Phone: 215/440-9300 FAX: 215/440-9313 E-mail: aacr@aacr.org

#### RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1997 annual dues for active members are \$175, \$100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$90 in 1997) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D. Executive Director

#### AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

#### APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE:_					DATE OF BIRTH:	
	LAST	FIRST	M.I.			
PRESENT POSITION/TITL	E:			- <del></del>		
INSTITUTIONAL AFFILIA	TION:					
INSTITUTIONAL ADDRES	SS:					
(City)	(State/Provin	ice)	(6	Country)	(Posta	l Code)
TELEPHONE NUMBER:			FAX			
PRIMARY FIELD OF RES. Biochemistry and BioCellular Biology andEpidemiologyPreclinical Pharmacol Experimental Therape  ACADEMIC DEGREES (In	physics Genetics ogy and utics	Biostatistics Clinical Investi Immunology Virology	gations _			ify)
PUBLICATIONS (Reprints these two articles list the auth number and year awarded.)	of two peer-reviewed a	rticles on which	the candidate appe	ears as an autho		
CANDIDATE IS APPLYIN	G FOR (Check one):	☐ ACTIVE	□ CORRESP		MEMBERSHIP	
NOMINATED BY*:	(Please print)		_ SECONDED	BY*:	Please print)	
STATEMENT OF SUPPO Instead of submitting letters I acknowledge by signing th long-term contribution to car	of recommendation, eit			-		
Signature of Nominator* See Guidelines for Applicati	on on the reverse side	Date	Signature of S			ate

(This form may be reproduced.)

\*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

#### AMERICAN ASSOCIATION FOR CANCER RESEARCH



#### GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

#### **QUALIFICATIONS FOR MEMBERSHIP**

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

#### **BENEFITS OF MEMBERSHIP**

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

- the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
- an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
- the privilege of registering for the annual meeting at the low associate member rate;
- 4. preferred access to the AACR Employment Register;
- optional subscriptions to the Association's high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
- priority notification of events in the AACR's series of special conferences on timely subjects in the field;
- 7. substantially reduced registration rates at special conferences;
- 8. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
- the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
- the facilitation of informal scientific exchange with leading researchers in the cancer field.

#### PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate

and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1996 are \$35 for associate members residing in the Americas and \$45 for residents of other countries. For 1997 these rates are \$45 and \$55, respectively. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

American Association for Cancer Research Public Ledger Building, Suite 816 150 S. Independence Mall West Philadelphia, PA 19106-3483 Phone: 215/440-9300

FAX: 215/440-9313 E-mail: aacr@aacr.org

#### RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1996 have been set at \$35 per year for residents of the Americas and \$45 for residents of other countries. For 1997 these rates are \$45 and \$55, respectively. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1996 for the forthcoming annual meeting must have paid dues for 1996. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1996 may retain associate membership until December 31, 2000. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D. Executive Director

#### AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

#### APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE:			· · · · · · · · · · · · · · · · · · ·	DAT	TE OF BIRTH:
	LAST	FIRST	M.I.		
INSTITUTIONAL AFFILIAT					
INSTITUTIONAL ADDRESS	}:		<u> </u>		
(City)	(State/P	Province)	((	Country)	(Postal Code)
TELEPHONE NUMBER:			FAX 1	NUMBER:	
PRESENT ACADEMIC STAGraduate StudentPhysician in Training	TUS/TITLE (Ple	ase check only one):Medical Stud	ent	JMBER (CARRIER):_	
PRIMARY FIELD OF RESE. Biochemistry and BiopiCellular Biology and GEpidemiologyPreclinical Pharmacolog Experimental Therapeu	hysics _ enetics _ gy and _	heck only one): Biostatistics Clinical Investige Immunology Virology		Carcinogenesis Endocrinology Molecular Biolog Other:	·
	se indicate degree				ition and date of receipt. Provide
RELEVANT RESEARCH EX	(PERIENCE NO	T RELATED TO CO	URSE WORK (PI	lease list most recent fi	irst.)
PUBLICATIONS (List the au candidate appears as an autho					-reviewed journal on which the
CANDIDATE NOMINATED	BY*:				
			(Plea	ase print)	
					structions on the reverse side of atements on this application are
Signature of Candidate:					Date:
I recommend this candidate for candidate is qualified for this					the best of my knowledge, the
Signature of Nominator*:					Date:
one copy of your curriculum v	itae. Enclose a ch	neck in U.S. funds, mad	le payable to AAC	CR, Inc., and drawn on	e nominator. In addition, submit a U.S. bank for one year's dues es. For 1997, these rates will be
Check one of the following be The enclosed dues payment sl	•	<u></u>			
					te will not be eligible to sponsor ation on the reverse side of this

<sup>\*</sup>Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

#### Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite WordPerfect (DOS, Windows,

Microsoft Word (DOS, Windows, and Macintosh)

and Macintosh) XyWrite (DOS and Windows)

#### Also acceptable:

**Ability** Mass 11 SoloWriter MS Windows Write **AmiPro Sprint** A, S-TEX MS Works Stx **Appleworks** MS Works WP Mac SunWrite ArborTEX Multimate Symphony TEX ArborText Multimate Advantage

ClarisWorks WP Nibia TEX78
CPT 8000 Nisus (to ASCII file) Text EXecutive

**CTOS** Notewriter **Textures** Diablo Obun Total Word Troff **DisplayWrite** OfficeWriter  $\mu TeX$ Duet PC Write Einstein PFS First Choice Volkswriter **VuWriter** Enable **Professional Write EXP Q&A** Write Wana OIS

Final Word Wang WPS Quark XPress RagTime MS Works Wang Writer **FullWrite** GemWord Plus (to ASCII file) Window Works Windows Write **IBM Writing Assistant** Rich Text Format Interleaf RSG (to ASCII file) WiziWord LATEX Signature Wordstar

Latex SLITEX Wordstar 2000
Leading Edge SmartWhere WriteNow
Lotus Manuscript SmartWrite II Xerox

Lotus Write

Software packages that we are unable to translate:

FrameMaker Ready, Set, Go PageMaker Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.

#### **DISK SUBMISSION FORM**

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

#### File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

Name used to access paper on disk:							
Name of computer used (e.g., IBM/PS2):							
Operating system and version (e.g., DOS 3.3):							
Word processing program and version (e.g., WordPerfect 5.0):	····						
[See reverse for acceptable programs.]							
Manuscript number:							
First author:							
Corresponding author (if different from first author):							
Telephone/FAX numbers:							

This form (both sides) may be reproduced.



#### LATE-BREAKING RESEARCH SESSION AT THE AACR ANNUAL MEETING Tuesday, April 15, 1997

Time has been set aside for the presentation of 4-5 definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:

#### INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS

- 1. The work to be presented must be of major novelty and significance, *e.g.*, the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.
- 2. The abstract must be sponsored by an AACR member in good standing (dues paid for 1997).
- 3. Each member in good standing may sponsor only **one** abstract for this session whether or not he or she sponsored an abstract last November for the regular annual meeting program. If an associate member is the **sponsor**, the abstract must also be **endorsed** by an active or corresponding member in good standing. In this case, the **endorser** does **not** forfeit the opportunity to **sponsor** a late-breaking abstract.
- 4. Abstracts must be typed on **one** side of **one** sheet of white paper.
- 5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm) with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.
- 6. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available **after** the annual meeting abstract deadline of November 12, 1996. This letter must contain the sponsor's complete mailing address, FAX number, and E-mail address (if available) so that we can communicate the scheduling decision of the Program Committee.
- 7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Time on March 7, 1997. FAX transmissions are not acceptable. Carrying envelopes should be clearly marked "Late-Breaking Abstract," and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the *Proceedings of the American Association for Cancer Research* has been printed; however, they will be distributed at the session in San Diego.
- 8. A special subcommittee of the Program Committee appointed by President Louise C. Strong will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than **March 24, 1997**.

## AACR SPECIAL CONFERENCE IN CANCER RESEARCH Co-Sponsored by the Joint Section on Tumors of the American Association of Neurological Surgeons and Congress of Neurological Surgeons

### **Cancer of the Central Nervous System**







June 7-11, 1997 Loews Coronado Bay Resort San Diego, CA

#### **CONFERENCE CO-CHAIRPERSONS**

Webster K. Cavenee / La Jolla, CA Peter McL. Black / Boston, MA

#### PROGRAM COMMITTEE

William F. Chandler / Ann Arbor, MI Joseph Piepmeier / New Haven, CT

Mark D. Noble / Salt Lake City, UT Bernd R. Seizinger / Boston, MA Jean Y. J. Wang / La Jolla, CA

#### CONFERENCE PROGRAM

Keynote Address Charles B. Wilson / San Francisco, CA

Triumphs and Challenges of Present Diagnosis and Management Catherine Dumas-Duport / Paris, France Peter McL. Black / Boston, MA Jay S. Loeffler / Boston, MA Victor A. Levin / Houston, TX

## Neurobiology and Developmental Biology

Fred H. Gage / La Jolla, CA Mark D. Noble / Salt Lake City, UT

Genetic Predispositions to CNS Tumors Jean Y. J. Wang / La Jolla, CA Lawrence A. Donehower / Houston, TX Eric C. Holland / Bethesda, MD Nikolai Kley / Boston, MA

Molecular Genetics
David N. Louis / Boston, MA
Huei-Jen Su Huang / La Jolla, CA
Otmar D. Wiestler / Bonn, Germany

New Targets for Therapy
Mark L. Rosenblum / Detroit, MI
David Hockenberry / Seattle, WA
Jerry W. Shay / Dallas, TX
Kevin Webster / Princeton, NJ

Receptor Mediated Growth Control Charles D. Stiles / Boston, MA Webster K. Cavenee / La Jolla, CA Lewis T. Williams / San Francisco, CA

Novel Therapies
Xandra O. Breakefield / Boston, MA
Jackson B. Gibbs / West Point, PA
Judah Folkman / Boston, MA
Frank McCormick / San Francisco, CA

#### ADDITIONAL SPEAKERS TO BE ANNOUNCED

Application Deadline: March 14, 1997

#### Information and Application Forms:

American Association for Cancer Research Public Ledger Building, Suite 816 150 South Independence Mall West Philadelphia, PA 19106-3483 215-440-9300 • 215-440-9313 (FAX)

E-mail: aacr@aacr.org Website: http://www.aacr.org



## AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES

#### APRIL 12-16, 1997 88th Annual Meeting

Chairperson: Frederick P. Li, Boston, MA Co-Chairpersons: Clara Derber Bloomfield, Buffalo, NY; Stephen H. Friend, Seattle, WA San Diego Convention Center, San Diego, CA

### JUNE 7-11, 1997 Cancer of the Central Nervous System

Conference with Neurosurgery Joint Section on Tumors

Chairpersons: Peter McL. Black, Boston, MA; Webster K. Cavenee, La Jolla, CA Loew's Coronado Bay Resort, San Diego, CA

## SEPTEMBER 9-13, 1997 Molecular Genetics of Cancer

Conference with the European Association for Cancer Research

Chairpersons: Eric J. Stanbridge, Irvine, CA; Walter Bodmer, Oxford, England Hertford College, Oxford, England

#### SEPTEMBER 26-30, 1997 Tumor Suppressor Genes

Chairpersons: Stephen H. Friend, Seattle, WA; Philip Branton, Montreal, Quebec, Canada Victoria Conference Centre, Victoria, BC, Canada

## OCTOBER 17-21, 1997 Gene Regulation in Differentiation and Development

Chairpersons: Robert Eisenman, Seattle, WA; Elaine V. Fuchs, Chicago, IL The Sagamore Resort, Bolton Landing (Lake George), NY

### DECEMBER 12-16, 1997 DNA Methylation and Cancer

Chairpersons: Peter A. Jones, Los Angeles, CA; Stephen B. Baylin, Baltimore, MD; Timothy Bestor, New York, NY El Conquistador Resort and Country Club, Las Croabas, PR

#### JANUARY 9-13, 1998 Programmed Cell Death

Chairpersons: John C. Reed, La Jolla, CA; Vishva M. Dixit, Ann Arbor, MI Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA

#### JANUARY 24-28, 1998 Angiogenesis and Cancer

Chairpersons: Judah Folkman, Boston, MA; Michael Klagsbrun, Boston, MA Hyatt Orlando, Orlando, FL

#### FEBRUARY 16-21, 1998 Innovative Molecular Biology Approaches to the Prevention, Diagnosis, and Therapy of Cancer

Joint Meeting with the Japanese Cancer Association Chairpersons: Edward Bresnick, Worcester, MA; Kaoru Abe, Tokyo, Japan Maui Marriott Resort, Maui, HI

AACR members will receive brochures on the above conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research Public Ledger Building, Suite 816 150 South Independence Mall West Philadelphia, PA 19106-3483 215-440-9300 • 215-440-9313 (FAX) E-Mail: aacr@aacr.org

For regular updates to this list visit the AACR's Website, http://www.aacr.org



#### AMERICAN ASSOCIATION FOR CANCER RESEARCH

#### **BENEFITS OF MEMBERSHIP**


The American Association for Cancer Research (AACR) is a scientific society consisting of over 11,000 laboratory and clinical cancer researchers. It was founded in 1907 "to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world." Members of the AACR enjoy the following benefits:

- the opportunity to subscribe to AACR's four prestigious journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention, at reduced member rates.
  - \* Cancer Research publishes about 6,300 pages per year of timely and significant research in the broad subfields of cancer research. With over 69,000 citations to its articles per year, it is the most highly cited journal in the cancer field and now ranks 16th among 10,000 scientific journals worldwide.
  - \* Clinical Cancer Research, a new AACR journal which was launched last year, already has about 4,500 subscribers, and encompasses both clinical and translational research. It publishes exciting clinical trials evaluating new treatments for cancer as well as preclinical studies that will lead to clinical trials.
  - \* Cell Growth & Differentiation, the Association's journal covering the molecular biology of cancer, is dedicated to bringing cutting-edge molecular cancer research rapidly to print. With over 2,000 subscribers, this monthly journal has established itself as an important source of significant new data in molecular oncology.
  - \* Cancer Epidemiology, Biomarkers & Prevention, which features new findings in cancer epidemiology, risk assessment and carcinogenesis, cancer prevention and control, and biomarkers for cancer detection, became a monthly publication in January 1996.
- the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting; (The AACR annual meeting is attended by more than 6,500 scientists from around the world and is the meeting you can't afford to miss. Scientists consider our annual meeting the most important multidisciplinary cancer meeting which encompasses basic research, clinical cancer research, and the exciting interface area of translational research.)
- an advance copy of the Program and *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
- · reduced registration rates at annual meetings;
- priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
- substantially reduced registration rates for Special Conferences;
- opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
- receipt of AACR Newsletters and other important announcements;
- · early notification of and reduced rates for participation in the AACR Employment Register;
- an up-to-date *Directory of Members* containing names and addresses of over 11,000 member researchers in the cancer field;
- the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
- the opportunity to participate in three **Summer Workshops** that foster knowledge in the cancer field for young investigators;
- the facilitation of informal scientific exchange with leading researchers in the cancer field; and
- · many more ongoing benefits.

## 66 CLINICAL CANCER RESEARCH

REPORTS NEW STUDIES THAT CAN
TRANSFORM RESEARCH FINDINGS INTO
ACTUAL INTERVENTIONS IN THE
MANAGEMENT OF CANCER PATIENTS.

John Mendelsohn, M.D. Editor-in-Chief, *Clinical Cancer Research* 



#### DON'T MISS A SINGLE ISSUE.

Clinical and translational investigations continue to have a dramatic impact on the treatment of cancer, making the need for up-to-date information increasingly important. Every month, basic and clinical cancer researchers turn to *Clinical Cancer Research* for the latest reports of significant new studies. Act now to ensure you receive research findings that are too important to miss.

**SUBSCRIBE TODAY** Call 1-800-875-2997 or 201-627-2427 or mail back the coupon below.

#### ORDER FORM

ORDER FORM						
✓ Yes! I'd like to subscribe!  Clinical Cancer Research  Vol. 3, 1997, 12 issues, ISSN 1078-0432  Institutional (Available only as a combined subscription with Cancer Research)	Method of Payment ☐ Enclosed check or money order in U.S. dollars drawn on U.S. bank. Payable to American Association for Cancer Research.					
□ \$685	Institutional purchase	is enclosed.				
☐ \$130 should be added for delivery outside the U.S.	☐ Please charge my	☐ MasterCard ☐ American Express	☐ VISA			
Individual						
☐ \$105 non-member ☐ \$40 should be added for delivery outside the U.S.  AACR members: Contact the AACR for rates, (215) 440-9300.			(40)			
Canada: Add 7% GST. MD: Add state sales tax.	Account Name					
Individual subscriber: I certify that this subscription is						
solely for my personal use and will not be used in a library.	Account No.					
Signature						
	Expiration Date					
Name						
Address						
	Signature					
City State Zip						
Country	Please send me Instru	ctions for Authors.				
Country  Mail coupon to: Clinical Cancer Research,	P.O. Box 3000 Denville NLO	7834-9359				
	can fax to: (215) 440-9354.	703173371				

#### THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS

## Three Outstanding Training Opportunities Supported by Major Grants from the National Cancer Institute Primarily for Postdoctoral and Oncology Fellows

Waiver of Registration Fees and Partial Subsidy of Lodging and Subsistence Expenses for Qualified Fellows

#### Molecular Biology in Clinical Oncology

A thorough overview of concepts in molecular biology designed for clinical oncologists in training

June 27-July 3, 1997, The Given Biomedical Institute, Aspen, CO Stephen H. Friend, L. Michael Glodé, and Jennifer A. Pietenpol, Organizers

- · Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology
- Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology
- Career development session and scheduled networking opportunities
- Application Deadline: March 31, 1997

.

#### Molecular Biology and Pathology of Neoplasia

(formerly entitled Histopathobiology of Neoplasia)

The Edward A. Smuckler Memorial Workshop

Intensive training in the molecular biology and morphology of human cancer for graduate students and postdoctoral fellows contemplating careers in basic cancer research

July 6-13, 1997, Keystone Resort, Keystone, CO Robert Low, Course Director

- · Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists
- An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators
- · Poster presentations by students and faculty to facilitate further scientific exchange
- Application Deadline: April 4, 1997

#### Methods in Clinical Cancer Research

Co-Sponsored by the American Society of Clinical Oncology (ASCO)

The essentials of clinical trials design for researchers at the level of fellow or junior faculty

July 26-August 1, 1997, Vail Cascade Resort and Club, Vail, CO Daniel D. Von Hoff and Charles A. Coltman, Jr., Chairpersons

- A series of lectures by leaders in the field covering all elements of clinical trials design
- Small group discussion sessions on important techniques in clinical research
- Development of a clinical trial protocol by all participants with detailed critiques by faculty members
- Category I CME credits through ASCO
- Application Deadline: April 21, 1997

Further Information and Application Forms Available from

American Association for Cancer Research • Public Ledger Building, Suite 816 • 150 S. Independence Mall West Philadelphia, PA 19106-3483 • Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: aacr@aacr.org